DNA gyrase inhibitors - Pipeline Insight, 2024

This “DNA gyrase inhibitors - Pipeline Insight, 2024” report provides comprehensive insights about 12+ companies and 13+ pipeline drugs in DNA gyrase inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

DNA gyrase inhibitors Understanding

DNA gyrase inhibitors: Overview

DNA gyrase is classified as topoisomerase II, an ATP-dependent enzyme. The enzymes plays vital role in transcription, replication of DNA and chromosome segregation processes in all bacteria except higher eukaryotes. Escherichia coli DNA gyrase is composed of two subunits, A and B. The active gyrase is a heterotetramer (A2B2). The GyrA N-terminal domain contains the site for DNA breakage and reunion while the C-terminal domain has a DNA wrapping function. The ability of DNA gyrase to introduce negative supercoils into DNA is a unique feature amongst all known type II topoisomerases. Therefore, this enzyme is desirable therapeutic target for development of new antibacterial agents.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence DNA gyrase inhibitors R&D. The therapies under development are focused on novel approaches for DNA gyrase inhibitors.

DNA gyrase inhibitors Emerging Drugs Chapters

This segment of the DNA gyrase inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

DNA gyrase inhibitors Emerging Drugs

TNP 2092: TenNor TherapeuticsTNP 2092 (CBR-2092) is a non-cleavable, rifampin-quinolone hybrid antimicrobial agent comprised of covalently conjugated rifamycin SV and 4H-4-oxo-quinolizine pharmacophores. The drug is in Phase II clinical studies for the treatment of bacterial infections and skin and soft tissue infections. In January 2020, TNP 2092 was granted Orphan Drug designation by the US FDA to treat prosthetic joint infections. TenNor has previously received FDA Qualified Infectious Disease Product (QIDP) and Fast Track designations for TNP-2092.

Zoliflodacin: Entasis TherapeuticsZoliflodacin (ETX0914) is an orally bioavailable antibacterial agent. It is a novel spiropyrimidinetrione bacterial DNA gyrase inhibitor. The drug is in Phase III clinical developmental studies for the treatment of gonorrhoea.

DNA gyrase inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different DNA gyrase inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on DNA gyrase inhibitors

There are approx. 12+ key companies which are developing the DNA gyrase inhibitors. The companies which have their DNA gyrase inhibitors drug candidates in the most advanced stage, i.e. Phase III include, Entasis Therapeutics.

Phases

This report covers around 13+ products under different phases of clinical development like

• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

DNA gyrase inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

DNA gyrase inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses DNA gyrase inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging DNA gyrase inhibitors drugs.

DNA gyrase inhibitors Report Insights

• DNA gyrase inhibitors Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

DNA gyrase inhibitors Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

• How many companies are developing DNA gyrase inhibitors drugs?
• How many DNA gyrase inhibitors drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for DNA gyrase inhibitors?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the DNA gyrase inhibitors therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for DNA gyrase inhibitors and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Entasis Therapeutics
• MerLion Pharmaceuticals
• TenNor Therapeutics
• Spero Therapeutics
• NeuroSense Therapeutics
• PolyActiva
• Ocumension Therapeutics
• Microbiotix

Key Products

• Zoliflodacin
• Finafloxacin
• TNP 2092
• SPR 720
• Celecoxib/ciprofloxacin
• Endophthalmitis preventive implant
• Moxifloxacin/dexamethasone
• SPR-719

Research programme: antibacterials


This product will be delivered within 2 business days.